Status: Recruiting
OM336 in Autoimmune Cytopenias
An early-phase clinical trial evaluating the safety, tolerability, and pharmacokinetics of subcutaneously dosed OM336 in adult participants with autoimmune cytopenias.
Participants needed: 32
Trial details
Phase: Phase 1Age: 18-75Biological sex: AllType: InterventionalSponsor: Lakefront Biotherapeutics West LLCUpdated: Jul 14, 2026Locations: 3
Eligibility criteria
Active autoimmune cytopenia [+3]
Previous treatment with a BCMA-targeted therapy [+3]